TrialClinical breast cancer2015

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

Ana M Gonzalez-Angulo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.